Drug Therapy for Rheumatoid Arthritis in Adults
Oral DMARDs Included in the Comparative Effectiveness Review
The oral disease-modifying anti-rheumatic drugs that have been studied for treatment of rheumatoid arthritis and were included in the comparative effectiveness review are:
Hydroxychloroquine: Its target of activity is uncertain but likely is T-lymphocytes.
Leflunomide: Its target of activity is pyridine synthesis.
Methotrexate: Its target of activity is dihydrofolate reductase and folate metabolism.
Sulfasalazine: Its target of activity is uncertain but may be multifactorial, including impairment of lymphocyte function and cytokine synthesis.
Keywords: anti-rheumatic | antirheumatic | biologic | cytokine synthesis | dihydrofolate reductase | disease-modifying | DMARDs | folate metabolism | hydroxychloroquine | leflunomide | lymphocyte function | methotrexate | oral | pyridine synthesis | RA | rheumatic | sulfasalazine | T-lymphocytes | rheumatoid arthritis
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.